Euronext Paris · Healthcare
Invest in AB Science stock from India
Indian and foreign residents can buy AB Science (AB) shares directly through Paasa.
By Paasa · Updated
AB Science at a glance
- Price
- €0.59+€0.00 (0.34%)
- Market cap
- €43.22M
- Day range
- €0.59 – €0.61
- P/E
- -15.01
- Dividend yield
- None
- Volume
- 312.23K
- 1 month
- -18.40%
- 6 months
- -49.57%
- YTD
- -61.69%
- 1 year
- -53.17%
- 5 years
- -95.42%
AB Science statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €1.2M | €1.1M | €970.0K | €958.0K | €1.6M |
| Gross profit | €720.0K | €1.2M | €587.0K | €927.0K | €1.5M |
| Operating income | −€1.2M | −€6.1M | −€13.4M | −€15.9M | −€13.8M |
| Net income | −€1.6M | −€7.8M | −€10.0M | −€13.6M | −€14.5M |
| Earnings per share | −€0.03 | −€0.15 | −€0.24 | −€0.29 | −€0.30 |
| EBITDA | −€1.2M | −€4.9M | −€12.8M | −€13.4M | −€17.4M |
| Total assets | €24.5M | €23.2M | €25.5M | €23.8M | €21.3M |
| Total debt | €4.2M | €18.5M | €19.1M | €24.0M | €8.4M |
| Cash and short-term investments | €10.2M | €8.0M | €6.1M | €7.3M | €8.7M |
| Shareholders' equity | −€17.2M | −€23.8M | −€21.0M | −€35.7M | −€23.2M |
| Operating cash flow | −€4.3M | €525.0K | −€16.9M | −€17.5M | −€17.2M |
| Free cash flow | −€4.6M | €370.0K | −€17.2M | −€18.1M | −€17.7M |
| Capital expenditure | −€282.0K | −€155.0K | −€345.0K | −€644.0K | −€564.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Median Technologies | ALMDT.PA | €3.70 | €179.66M |
| Affluent Medical | AFME.PA | €2.81 | €110.43M |
| Eurofins-Cerep | ALECR.PA | €16,100.00 | €81.21M |
| Crossject | ALCJ.PA | €1.35 | €80.92M |
| Fermentalg | ALGAE.PA | €0.44 | €52.59M |
| Theraclion | ALTHE.PA | €0.70 | €51.18M |
| Sensorion | ALSEN.PA | €7.84 | €47.96M |
| Klea | ALKLH.PA | €0.12 | €37.83M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in AB Science from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search AB and buy
Find AB Science by name or by its ticker, AB, and place your order.
Why invest in AB Science from India
What AB Science does
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. AB Science operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy AB Science stock from India?
Yes. Indian residents and NRIs can buy AB Science (AB) shares directly through Paasa. AB Science is listed on Euronext Paris, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell AB Science shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.